News | August 11, 2021
Marksons Pharma PAT at Rs 62.6 cr. for Q1FY22
The company has tied up with OrbiMed as a financial partner for global reach
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Deal signed with AOP Orphan for US commercial rights
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Company working on COVID vaccine INO 4800
A veteran in cell therapy and oncology commercialisation
Subscribe To Our Newsletter & Stay Updated
